Maple Health Group
Maple Health Group is a global strategy consulting firm specializing in Health Economics and Market Access, serving pharmaceutical, biotech, and medical device companies since 2015. Headquartered in New York City and operating in nearly a dozen countries, the company is committed to delivering work that exceeds client expectations through expertise in strategic health economics, HTA strategy, and economic modeling.
Industries
Nr. of Employees
small (1-50)
Maple Health Group
142 West 57th Street, 11th Floor, New York, NY 10019
Services
Consulting engagements to identify payer evidence needs, design value propositions, and develop strategic market access plans across jurisdictions.
Development of cost-utility, cost-effectiveness and budget impact models, systematic reviews, and meta-analyses to support HTA and payer decision-making.
Creation of payer-facing communication materials including dossiers, slide decks, annotated references, publications, and conference materials to convey product value.
Consulting engagements to identify payer evidence needs, design value propositions, and develop strategic market access plans across jurisdictions.
Development of cost-utility, cost-effectiveness and budget impact models, systematic reviews, and meta-analyses to support HTA and payer decision-making.
Creation of payer-facing communication materials including dossiers, slide decks, annotated references, publications, and conference materials to convey product value.
Expertise Areas
- Market access strategy
- Health economics and HTA strategy
- Economic modelling (cost-effectiveness and budget impact)
- Evidence synthesis and network meta-analysis
Key Technologies
- Cost-effectiveness modelling
- Budget impact modelling
- Microsimulation modelling
- Bayesian network meta-analysis
News & Updates
Development of a cost-utility and budget impact model to demonstrate the economic value of PRODUCT X in R/R ALL, including adaptations for different countries.
Network meta-analysis to assess the clinical value of PRODUCT X in RRMS.
Development of an AMCP dossier for PRODUCT X to aid US payers in formulary decision-making.
Development of a cost-utility and budget impact model to demonstrate the economic value of PRODUCT X in R/R ALL, including adaptations for different countries.
Network meta-analysis to assess the clinical value of PRODUCT X in RRMS.
Development of an AMCP dossier for PRODUCT X to aid US payers in formulary decision-making.